Ultravate (halobetasol proprionate) / Sun Pharma - LARVOL DELTA

Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potential. (PubMed, JAAD Int) - "Small sample size. The HBP lotion 0.05% appeared efficacious and well tolerated in patients as young as 12 years old."

Clinical • Journal • Dermatology • Immunology • Psoriasis

Comparison of effectiveness of topical Tacrolimus 0.1% vs topical Halobetasol Propionate 0.05% as an add-on to oral Hydroxychloroquine in Discoid Lupus Erythematosus. (PubMed, Dermatol Ther) - "The present study demonstrated that tacrolimus 0.1% ointment and halobetasol propionate 0.05% ointment had a comparable efficacy in DLE patients; however, halobetasol showed significantly better improvement regarding scaly, hypertrophic lesions."

Journal • Cutaneous Lupus Erythematosus • Dermatology • Discoid Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Rheumatology

[VIRTUAL] Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area (FCDC 2020) - "Abstract not available."

Clinical • Dermatology • Immunology • Psoriasis

[VIRTUAL] Therapeutic Update (FCPANP 2020) - "Goldenberg highlighted the advances in vehicles that have made new formulations possible, including topical tretinoin lotion, topical tazarotene foam, topical 4% minocycline foam, a new first-in-class topical androgen receptor inhibitor Clascoterone (approved for patients 12 years old and up), as well as new data that combination adapalene 0.3% and benozyl peroxide 2.5% gel can reduce the risk of atrophic scar formation within 24 weeks. Oral medications, including a more selective tetracycline, sarecycline, and low-dose micronized isotretinoin, have also shown efficacy while reducing the adverse effects and concerns of their predecessors (e.g. antibiotic resistance and need for concurrent high-fat/high-calorie meals respectively)...This is made possible by advancements such as oxymetazoline cream 1.0% for people with more erythema and telangiectasias, or the use of minocycline 1.5% topical foam, azelaic acid 15% topical foam, ivermectin 1% topical cream and improved..."

Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Pruritus • Psoriasis • Rosacea • Skin Cancer • IL13 • JAK3 • TNFA • TYK2

[VIRTUAL] Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12% (FCPANP 2020) - "Abstract not available."

Clinical • Dermatology • Immunology • Psoriasis

[VIRTUAL] Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis (FCDC 2020) - "Abstract not available."

Clinical • P4 data • PK/PD data • Dermatology • Immunology • Psoriasis

[VIRTUAL] Combination of Calcipotriene 0.005% Foam and Halobetasol Propionate 0.05% Foam in the Treatment of Scalp Psoriasis (FCPANP 2020) - "Abstract not available."

Dermatology • Immunology • Psoriasis

[VIRTUAL] Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion (FCDC 2020) - "Abstract not available."

Clinical • Dermatology • Immunology • Psoriasis

[VIRTUAL] Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study (FCPANP 2020) - "Abstract not available."

Clinical • Dermatology • Immunology • Psoriasis

Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. (PubMed, Ann Pharmacother) - "Data Sources: A systematic search (January 2005 to July 2019) of MEDLINE (PubMed) and EMBASE databases was performed using the terms halobetasol, tazarotene, halobetasol/tazarotene, Duobrii, and IDP-118. Drug synergy may play a role. Importantly, patient adherence to a once-daily combinational therapy is likely to contribute to efficacy."

Clinical • Journal • P2 data • P3 data • Dermatitis • Dermatology • Immunology • Pain • Pruritus • Psoriasis

Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age. (PubMed, Pediatr Dermatol) - "Much like other medications for AD treatment, TCS are sometimes used off-label. The off-label use of topical corticosteroids to treat pediatric AD highlights a gap between clinical practice and regulating guidelines. Additional pediatric studies would offer a greater body of evidence to maintain or expand label indications for the use of TCS in younger patients."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020. 23:6, 641-649. (PubMed, J Med Econ) - No abstract available

HEOR • Journal • Dermatology • Immunology • Psoriasis

Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report. (PubMed, J Drugs Dermatol) - P3 | "2020;19(10):1000-1004. doi:10.36849/JDD.2020.5347."

Clinical • Journal • Dermatology • Immunology • Psoriasis

Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants. (PubMed, J Drugs Dermatol) - "J Drugs Dermatol. 2020;19(8): doi:10.36849/JDD.2020.5250."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis

Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults. (PubMed, Clin Cosmet Investig Dermatol) - "Here, we review the important clinical efficacy and safety data derived from pivotal clinical trials for HP/TAZ in the treatment of plaque psoriasis. We also discuss the mechanism of action, dosage guidelines, pharmacokinetics/pharmacodynamics, and clinical considerations for HP/TAZ, including why HP/TAZ should be avoided in pregnant patients."

Clinical • Journal • Review • Dermatology • Dermatopathology • Immunology • Psoriasis

[VIRTUAL] Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion (SID 2020) - "These data indicate a longer maintenance of therapeutic effect with HP 0.01%/TAZ 0.045% lotion. Funding: Ortho Dermatologics"

Clinical • Dermatology • Dermatopathology • Immunology • Psoriasis

Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females. (PubMed, J Drugs Dermatol) - "HP/TAZ lotion was highly effective and safe in both males and females with moderate-to-severe psoriasis over 8 weeks of once-daily use. J Drugs Dermatol. 2020;19(5): doi:10.36849/JDD.2020.5021."

Journal • P3 data • Dermatitis • Dermatology • Dermatopathology • Immunology • Pain • Psoriasis

DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults. (PubMed, Skinmed) - No abstract available

Clinical • Journal • Dermatology • Dermatopathology • Immunology • Ophthalmology • Psoriasis

Long-term safety results from a Phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis. (PubMed, J Am Acad Dermatol) - No abstract available.

Clinical • Journal • P3 data • Biosimilar • Dermatology • Dermatopathology • Immunology • Psoriasis

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy. (PubMed, J Drugs Dermatol) - "In conclusion, HP 0.01%/TAZ 0.045% lotion provides synergistic efficacy following 8 weeks' therapy that is sustained after a 4-week posttreatment period. J Drugs Dermatol. 2018;17(7):723-726."

Clinical • Journal • Biosimilar • Dermatology • Immunology • Psoriasis

Nanostructured lipid carriers loaded with Halobetasol propionate for topical treatment of inflammation: Development, characterization, biopharmaceutical behavior and therapeutic efficacy of gel dosage forms. (PubMed, Int J Pharm) - "After application of the formulations in volunteers, no irritation, redness or edema reactions were detected, plus, an enhancement of the biomechanical properties of the skin was evidenciated. Therefore, the results indicate that this formulations are a suitable alternative to current treatments."

Clinical • Journal • Immunology

Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration. (PubMed) - J Drugs Dermatol - "Both formulations of HBP (Lotion and Cream) contributed to skin moisturization, as measured by skin conductance. HBP Lotion produced a significantly more rapid onset and higher level of moisturization at 2 and 4 hours post-application compared to HBP Cream. The TEWL results indicate that neither HBP Lotion nor HBP Cream provided any significant occlusivity to the skin. J Drugs Dermatol. 2017;16(2):140-144."

Journal • Biosimilar • Inflammatory Bowel Disease

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis (clinicaltrials.gov) - P2; N=154; Completed; Sponsor: Valeant Pharmaceuticals International, Inc.; Recruiting ➔ Completed; Trial primary completion date: Sep 2016 ➔ Dec 2016

Trial completion • Trial primary completion date • Biosimilar • Immunology • Psoriasis

Drug updates and approvals: 2019 in review. (PubMed, Nurse Pract) - "In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent)."

Journal